Sarsam @sclerodermaUM et al. Long term follow up of abatacept in SSc (ASSET). @RheumNow #ACR22 Abstr#1521 https://t.co/BvWSSSIqN0 https://t.co/kc2HxjkVh8

• Long-term Follow-Up of Participants of the Phase II Study That Evaluated Subcut…

Another poster from my research group! Investigated recommendations in ACR/EULAR guidelines <1/6th informed by head 2 head RCT We need more comparative effectivness research! #ACR22 @RheumNow #1284 https://t.co/HQoeKj0cxy

Moura et al. 22 case series of VEXAS. Lung involvement common, Symptoms in 95%. HRCT abnormal 73%. PFTs abnormal 20%. Changes non specific inflammatory parenchymal, steroid responsive. @RheumNow #ACR22 Abstr#1569 https://t.co/E6vUnvxSdQ https://t.co/l4aEmpy8OX

• Lung Involvement in VEXAS Syndrome - ACR Meeting Abstracts

Fukui et al. Association different alcoholic drinks and urate in Japan. Patients always ask about this. We should drink more sake it seems! @RheumNow #ACR22 Abstr#1206 https://t.co/En5pSMUNp7 https://t.co/c67r9fsHJT

• Association Between Different Alcoholic Beverages and Serum Urate Level: A Cros…

Exciting trial for PMR, SAPHYR RCT of sarilumab (IL6) in relapsing/refractory PMR I interviewed Robert Speira aobut the trial for @RheumNow, arriving to your podcast inbox! Overall very exciting, need options for this group and nice to see PMR getting attention #ACR22 #ACRBest https://t.co/nPurVhpNws

Johnson et al. Increased risk of heart failure and heart failure mortality in RA. No improvement over time. @RheumNow #ACR22 Abstr#1204 https://t.co/MGEgmORGuL https://t.co/9zDYjZiCh1

• An Increased Risk of Heart Failure and Heart Failure-Related Death Persists in …

Ferrada @maferradastrong et al. HSCT in VEXAS. 20 evaluated. Indications refractory disease or haematologic abnormalities. Completed in 2, ongoing in 2. @RheumNow #ACR22 Abstr#1568 https://t.co/01SeHQcIsh https://t.co/XCgz4cTQCJ

• Evaluation for Allogeneic Hematopoietic Stem Cell Transplant Indications and El…

What to do? Should you cycle TNFi in PsA and SpA or move on? 86 Pts from CorEvitas w PsA or Ankylosing spondylitis. TNF switching was not a home run - at 6 mo on 2nd TNF only 15% were in low disease activity. 21% persistence at 2 yrs. Use another Rx! Abst#1499 #ACR22 @rheumnow

Inflammation causing HTN in AS? Abstract #0384 #ACR22 @RheumNow 🫀413 patients followed for median 12 years 🫀14% developed HTN 🫀Baseline disease duration was an independent RF for HTN 🫀ESR > 20 sig. associated with HTN

Martín-Varillas et al. ADA vs certolizumab in Cystoid Macular Edema in Behcets. "Equally" effective here but 80% of the certolizumab patients were previously refractory to ADA. @RheumNow #ACR22 Abstr#1567 https://t.co/ZKr38i2iA5 https://t.co/Jbtqlv9YAF

• Refractory Macular Edema Due to Behçet&#039;s Disease. Multicenter Comparative …

Kayadibi et al. Venous halo sign in Behcets. 86% of Behcets thrombophlebitis vs 13% non-Behcets @RheumNow #ACR22 Abstr#1251 https://t.co/fnSDYhaFa0 https://t.co/luIZH9SHwW

• Venous Halo Sign Detected with Superb Microvascular Imaging in Behçet Syndrome …

Ab1011 #ACR22 @SMerjanah: Fracture rates among vets with AS Increasing fx incidence for AS and comparator groups over time There was increase in fractures during TNFi era 2004-2021 compared to pre-TNFi, does not show fx sparing effect @RheumNow https://t.co/fTSYbFcxqo

Wiebe et al. Steroids <=5mg/day not associated negative effect on BMD. Of course steroid-related increase in fracture risk is not fully captured by BMD effect @RheumNow #ACR22 Abstr#1318 https://t.co/Ond5gzopRa https://t.co/HX2AUyQmsf

• Low-Dose Prednisolone (≤5 Mg/d) Is Not Associated with Deleterious Effects on B…

#ACR22 Abstr#1569 Lung complications are common in #VEXAS but what are the common radiologic findings? A cohort study in 22 men showed abnormalities were found in most patients but were non-specific. Most commonly parenchymal changes (73%) @RheumNow https://t.co/kjYSHON2yN

Carter et al. Case series showing rapid effect of anifrolumab in refractory discoid lupus and SCLE. @RheumNow #ACR22 Abstr#0974 https://t.co/RjnNxjGJoP…

• Rapid and Effective Response to Immunosuppression in Treating Macrophage Activa…